Aptose Biosciences Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q2 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Aptose Biosciences Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2017 to Q3 2024.
  • Aptose Biosciences Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was -$13K, a 102% decline year-over-year.
  • Aptose Biosciences Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $1.41M, a 65.5% decline year-over-year.
  • Aptose Biosciences Inc. annual Share-based Payment Arrangement, Expense for 2023 was $3.65M, a 29.8% decline from 2022.
  • Aptose Biosciences Inc. annual Share-based Payment Arrangement, Expense for 2022 was $5.21M, a 59.8% decline from 2021.
  • Aptose Biosciences Inc. annual Share-based Payment Arrangement, Expense for 2021 was $12.9M, a 39.6% decline from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $1.41M -$13K -$612K -102% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 $2.03M $207K -$562K -73.1% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $2.59M $809K -$1.07M -56.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 $3.65M $411K -$450K -52.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-26
Q3 2023 $4.1M $599K -$454K -43.1% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 $4.56M $769K -$10K -1.28% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $4.57M $1.87M -$640K -25.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 $5.21M $861K -$1.45M -62.8% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-26
Q3 2022 $6.66M $1.05M -$775K -42.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $7.44M $779K -$1.39M -64% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 $8.82M $2.51M -$4.13M -62.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 $12.9M $2.31M -$2.12M -47.8% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-24
Q3 2021 $15.1M $1.83M -$3.08M -62.7% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-01
Q2 2021 $18.1M $2.16M -$5.54M -71.9% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-02
Q1 2021 $23.7M $6.64M +$2.24M +50.9% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 $21.4M $4.43M +$3.87M +688% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-22
Q3 2020 $17.6M $4.91M +$4.4M +873% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 $13.2M $7.7M +$7.13M +1256% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-03
Q1 2020 $6.04M $4.4M +$3.74M +565% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-04
Q4 2019 $2.3M $562K -$20K -3.44% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-23
Q3 2019 $2.32M $504K -$447K -47% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-10
Q2 2019 $2.76M $568K +$53K +10.3% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-04
Q1 2019 $2.71M $662K -$1.57M -70.3% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-05
Q4 2018 $4.28M $582K Oct 1, 2018 Dec 31, 2018 10-K 2020-03-10
Q3 2018 $951K +$796K +514% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-05
Q2 2018 $515K +$66K +14.7% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-06
Q1 2018 $2.23M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-07
Q3 2017 $155K Jul 1, 2017 Sep 30, 2017 8-K 2019-03-12
Q2 2017 $449K Apr 1, 2017 Jun 30, 2017 8-K 2019-03-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.